Immunome, Inc. (NASDAQ:IMNM) Short Interest Update

Immunome, Inc. (NASDAQ:IMNM) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 9,870,000 shares, a growth of 12.2% from the December 15th total of 8,800,000 shares. Based on an average trading volume of 787,000 shares, the short-interest ratio is currently 12.5 days. Currently, 19.2% of the shares of the company are sold short.

Immunome Trading Up 1.3 %

NASDAQ:IMNM opened at $9.99 on Monday. The business’s fifty day moving average price is $11.47 and its 200 day moving average price is $12.92. The firm has a market capitalization of $623.58 million, a price-to-earnings ratio of -1.23 and a beta of 1.90. Immunome has a 1-year low of $8.97 and a 1-year high of $30.96.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IMNM. Stephens started coverage on Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Monday, January 13th. Finally, Piper Sandler decreased their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome has an average rating of “Buy” and a consensus target price of $28.83.

Insiders Place Their Bets

In related news, CTO Philip Tsai purchased 21,000 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average price of $9.43 per share, with a total value of $198,030.00. Following the acquisition, the chief technology officer now owns 21,000 shares in the company, valued at approximately $198,030. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Robert Lechleider acquired 15,805 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were bought at an average price of $9.48 per share, with a total value of $149,831.40. Following the completion of the purchase, the insider now owns 15,805 shares in the company, valued at $149,831.40. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 102,862 shares of company stock valued at $978,045 over the last quarter. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP raised its stake in shares of Immunome by 228.5% during the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after purchasing an additional 1,191,774 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Immunome by 10.3% in the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after acquiring an additional 324,614 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after acquiring an additional 302,916 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after purchasing an additional 237,497 shares during the last quarter. Finally, AXA S.A. bought a new position in shares of Immunome during the 2nd quarter valued at $2,174,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.